Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro.
Lin
T S
TS
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, USA.
Luo
M Z
MZ
Liu
M C
MC
Zhu
Y L
YL
Gullen
E
E
Dutschman
G E
GE
Cheng
Y C
YC
D000998:Antiviral Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D015195:Drug Design; D006678:HIV / Q000187:drug effects*; D006515:Hepatitis B virus / Q000187:drug effects*; D006801:Humans; D016047:Zalcitabine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology
D000998:Antiviral Agents; D016047:Zalcitabine; C050624:2',3'-dideoxycytidinene; C099405:dexelvucitabine